ReNerve Limited is pleased to present its Quarterly Activities Report for the period ended 31 March 2025. Key highlights include the clinical validation of the NervAlign® Nerve Cuff, showing superior pain reduction and enhanced patient satisfaction. Financially, Q3 FY25 saw a 39% increase in sales, disciplined cost management, and a robust cash reserve of A$5.8 million.<br/><br/>During the quarter, ReNerve saw growth in sales, expanded through partnerships, and appointed a new VP of Sales and Marketing in the US. Positive clinical study data for the NervAlign® Nerve Cuff was presented, reinforcing its benefits in peripheral nerve repair procedures. The company remains focused on commercial momentum and innovation, with a strong focus on long-term product development.<br/><br/>The NervAlign® Nerve Cuff is gaining adoption in various surgeries and has a clear pathway for FDA clearance of additional products. Recent clinical research demonstrated significant improvements in patient outcomes, highlighting the product's effectiveness. Financially, the company received a significant tax incentive refund and continued its disciplined approach to capital allocation.<br/><br/>Investors are encouraged to inquire for further details or questions regarding the report. ReNerve remains well-funded to achieve its strategic objectives and drive innovation in peripheral nerve repair solutions. For more information, contact CEO Dr. Julian Chick or Investor & Media Relations at ReNerve.